Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
Roland B. Walter(University of Washington), Elihu H. Estey(University of Washington), Megan Othus(Cancer Research And Biostatistics), Thomas Pabst(University Hospital of Bern), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Gert J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bob Löwenberg(Erasmus MC), Alan K. Burnett(Cardiff University), Frederick R. Appelbaum(University of Washington), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Sherry R. Pierce(The University of Texas MD Anderson Cancer Center), Anna Evans(Cardiff University)
Cited by 172
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k